Santhera shares updates on commercial rollout of AGAMREE®


Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD).

Continued here:
Santhera shares updates on commercial rollout of AGAMREE®

Related Posts